

Serum Protein Electrophoresis Plays a Role in the Diagnosis of Multiple Myeloma in Baghdad City Patients.

Entesar J. Fadel¹, Qader Abdullah Shannak², Mustafa A. J. Alhiti^{*3} and Shahad M. Ali⁴

- (¹) MSc. Organic Chemistry, In Disease and Histopathological Laboratory, In Biotechnology & Environmental Center, In Fallujah University/Bagdad / Iraq
- (²) MSc. Inorganic Chemistry, In Disease and Histopathological Laboratory, In Biotechnology & Environmental Center, In Fallujah University/Bagdad / Iraq
- (³) BSc. Agri. in Pathological Analysis Laboratory, In Biotechnology & Environmental Center, In Fallujah University/Bagdad / Iraq.
- (⁴) BSc. Chemistry, Pharmacy Technologies Laboratory, In Insatiate of Medical Technology / Al-Mansour, Middle Technical University.

* Corresponding Author: Mustafa A. J. Alhiti

E-mail: Mustafa.j.alhiti@uofallujah.edu.iq

Abstract:

Multiple Myeloma (M.M) is an uncontrolled accumulation of irregular plasma cells that is described by a cell line neoplasm B, which secretes abnormal immunoglobulin, which triggers monoclonal gammopathy, identified by the occurrence of M protein in serum, and the aim of this study To define, measure, and distinguish between monoclonal gammopathy and benign disorders in reported cases of multiple myeloma, since the prognosis and treatment, vary widely from each other. The method of the serum samples for 112 alleged cases was divided into two parts, males and females, and the number of males in this study was 56, and the same number of females is subject to cellulose acetate strip serum protein electrophoresis. Visually sensed M band and densitometer estimated M protein. In M band positive cases, bone marrow biopsy and clinical profile have been associated in Serum Protein Electrophoresis by SEBIA Capillary company, and the result of 112 instances of monoclonal gammopathy was diagnosed. A multiple myeloma diagnosis was rendered in percent of cases, and an undetermined case of monoclonal gammopathy was identified. Conclusion of this survey SEBIA is an easy-to-use laboratory procedure in diagnosis serum protein electrophoresis that is used to diagnose and measure monoclonal gammopathy and can be prescribed for confirmed multiple myeloma cases as a preliminary test.

Introduction:

Multiple Myeloma is an uncontrolled development of irregular plasmic cells in the B cell lineage neoplasm. These dysfunctional plasma cells secrete an abnormal immunoglobulin, which is known as monoclonal gammopathy, and can be seen in serum and urine electrophoresis through the inclusion of the M protein [1]. It constitutes 10% of malignancies in blood [2]. Other diseases of plasma cells may include micro-cytosis, myeloma, and other hematological diseases, including monoclonal gammopathy (also known as MGUS). Plasma cell disease signs are suspected of being back pain, nausea or exhaustion, osteopain, osteolytic lesions, accidental fracture, and chronic infection [3]. Differentiating between M.M. is quite critical. The involvement of M.M or the reality that there is M. in the majority doesn't alter how imaginative you are. And, on top of that, ME or MEGUS. The creation of robots is radically different from computers. Computers have just one purpose: knowledge retrieval. Robotics strives to fulfill a larger purpose: they are designed to build and kill. The number of artists in the world is around 4,000,000[4] and of monoclonal undetermined gammopathy is an approximate breakdown, for those 50 years of age, is 1% of the elderly, 3% of the elderly, and 9% of the elderly. [5-7]. In comparison, in these two conditions, the requirement for treatment is often very distinct.

Serum protein electrophoresis is used to examine monoclonal granulocytosis and map out the amount of the M protein to estimate how much of it is present in patients with multisite discomfort, bone lesions, and leukocytosis, as well as other universal symptoms in order to assess whether or not the patient has monoclonal gammopathy. SPEP is a basic laboratory technology in which serum is added and subjected to an electric current on the medium assisted.

The various sections of the serum proteins, such as the globulin fractions. In the interpretation of serum protein electrophoresis analyses, the gamma globulins are the preferred analytes of preference. Although a number of external influences may increase in the Gamma range, key influencing factors are important for those which produce a homogenous gamma peak. We have ended up with a single, typically malignant plasma cell clone or a monoclonal class of immunoglobulin or a mixture of the two of which have monoclonal light chains. Proteins are also proteins (monoclonal).

Since a point symmetric spike (with alpha and beta electrodes) can readily sense the protein's movement, a M spike is called an M. The most frequent source of paraproteinemia is multiple myeloma [8,9]. Monoclonal gammopathies include malignancy, such as cell plasma dyscrasias, recurrent lymph leukaemia, and unexplained brain idiopathic types. The medications (diphenyl hydantoin, sulfonamide and penicillin) may be correlated with them [10].

AIM: In reported cases of multiple myeloma, diagnose and measure monoclonal gammopathy with serum protein electrophoresis.

Materials and methods:

The structures of Sebia use a free solution of capillary electrophoresis. Due to their mobility in an alkaline buffer, charged molecules are isolated with the specific pH. Electrolyte pH and electroosmotic flow are isolated from each other. A variety of parallel capillaries are given for the Sebia capillary electrophoresis instruments that enable several simultaneous analyses:

❖ Flex Piercing from MINICAP (2 capillaries)

Each sample is dissolved into a dilution buffer, with a separation buffer filling the capillaries, and samples are then inserted into the capillary's anodic end. A high voltage protein break-up is then done and the various protein fractions are specifically identified and quantified at the cathodic end of the capillary on a particular wavelength. After examination, a wash solvent is used to clean the capillaries and then re-filled with the buffer to ready the next samples.

Result:

Positive M band seen in serum protein electrophoresis of the effected 112 scientifically cases of multiple myeloma were sent during the period February/2019 - February/2020 in the Alharthya-gene private laboratory. In the infected cases of monoclonal gammopathy, 16 (10.6 percent) were found to be. 70% of them are male and 30% of them are female. Thus, the bulk of the patients (52-66%) were aged 51 to 66 years and the others (31-57%) were in the 61- to 70-year range [Table 1].

Table 1: Showing percentage of different serum protein electrophoresis pattern

Parameters	Groups	
	Female (n=56)	Male (n=56)
ALB	51.3 ± 1.03*	49.3 ± 1.5
Alpha1	5.5 ± 0.2	6 ± 0.2

Alpha2	12.2 ± 0.5	11.5 ± 0.4
Beta1	6.2 ± 0.2	5.6 ± 0.3
Beta2	7.5 ± 0.8	6.3 ± 0.6
Gamma	17.3 ± 1	20.5 ± 1.3*
T.P	66.4 ± 0.8	63.9 ± 1.4
AG ratio	1.11 ± 0.05	1.07 ± 0.5
* Significant at P<0.05		

Among these, the gamma (μ) band was 14 (87.5 per cent) and the beta (β) globin band is 2 (12.5 per cent). In the area of α there was no M unit. The mean protein concentration in the μ area was 5,3 g/dl, 3 to 7 g/dl, 2,5 g/dl, 2-3 g/dl and β , respectively. The M spike within the β area was depicted in the [Fig-2] and the serum protein electrophoresis trend in [Fig-3] in Cellulose acetate, though, continues to form polymers in oligoclones when it is attached to other covalent polymers.




Fig-2 graph showing M spike in gamma region in infected cases




Fig-3 Graph showing normal pattern in this study




Fig-4:GraphPara protein fractions frequency. Total number = 112

The M-band positive cases have been collected from the bone marrow biopsy results. 15 individuals (10 percent) were diagnosed with myeloma, and one person (0.76 percent) had MGUS laterrelating monoclonal gammopathy through biopsy of the bone marrow and cline activity. Proportion of myeloma cells in the bone marrow in cases of multiple myeloma was variable and ranged from 12% to 65%. In addition to para-proteinaemia, the chronic inflammation model, acute inflammation, anaemia of the iron deficiency.

Discussion:

A terminally segregated plasma cell cancer, multiple myeloma, usually happens in patients of older age. This disorder has a low prevalence, about 1% of all cancers, but after age 60, the frequency is increasing [11]. The word 'multiple myeloma,' which implies the tumor cell (oma) aggregation at several points in the bone marrow (myelo), defines a characteristic function. Plasma cells normally comprise 1% of cells in the bone marrow, then the tumor consignment in the bone marrow, as the disease progresses, grows to 80%, depending on the nature of the disease. The malignancy in these plasma cells

Monoclonal circulatory antibodies that are produced. Therefore, the blood amount of the monoclonal protein (antibody) Growing [12]. Serum protein electrophoresis is widely employed in clinical practice to diagnose many myeloma and other serum protein abnormalities. In the initial assessment of various health disorders, several experts use serum protein electrophoresis as a diagnostic test [12,13].

In our report, 112 supposed to be cases of myeloma were monoclonally gammopathic or paraproteinemic, relative to 24.4 percent of Col. Chopra et al., with M-protein positive samples by SPEP[10]. The samples recorded by MD Dilawer et al. 9.2 percent[14] and by Vijayashree N 4.8 percent of paraproteinaemia samples were reported in their studies[15]. The M rise in the gamma area in 14 (87.5%) and 2 (12.5%) cases in the beta region is amongst the 16 M band positive cases that we examined. In 84.8% of the instances, Col.G S Chopra et al registered M in the gamma (γ) region, and in an M-spike in the beta (β) globalin district, there was a 15.2% spike[10]. The male to female ratio in our sample was 1.7:1, while in its study Col GS Copra et al. [10] the ratio was 1.2:1. [10]. In the research conducted by Nayak B S et al., there was also a small male prevalence[16].

The condition occurred in women later than in male patients. (In males between 51 and 60 years of age and in females between 61 and 70 of age). The guidelines for diagnosis offered by Durei BG and Kyle RA is met by our multifarial myeloma patients [17,18]. In our sample, 15 cases (10%), as they had upper 10% myeloma cells in the bone marrow and > 3 g/dl of M protein in serum protein electrophoresis, were diagnosed as multiple Myeloma. MGUS is the definition initially coined by the Mayo Group[19]. MGUS is an indeterminate gammopathy with undetermined meaning. In the stable geriatric community, the prevalence of monoclonal gammopathy approaches as much as 8%[20]. Patient that suffering from MGUS need follow-up, as approx. 2 per cent acquire several myeloma or other malevolent monoclonal gammopathy each year [21,22,23].

Detection of MGUS. is a difficulty in clinical practice because of its asymptomatic existence. A MGUS-asymptomatic patient is the diagnosis criterion given by the International Myeloma Working Group[25]. The < 10 percent plasma cells b marrow. Bone marrow. The patient has a band of the beta but was asymptomatic, with an MGUS follow-up instances.

Conclusion:

Serum Protein lectrophoresis is a simple laboratory test and can be used in monoclonal gammopathy diagnosis and quantification. It can be carried out. M Protein of the bone marrow (< 3 g dl). M Protein of the serum was could not detect the immunoglobulin isotype.

Boundaries:

The detection of monoclonal immunoglobulins and the recognition of a broad or light chain isotype is more sensitive than the serum protein electrophoresis immunofixation (IFE). Owing to a shortage of IFE in our laboratory, we did not detect immunoglobulin isotype.

References:

1. **Abdalla IA, Tabbara IA.** Nonsecretory multiple myeloma. South Med J. 2002;95(7).
2. **Adnan AZ, David HV.** Multiple myeloma: an old disease with a new hope for the future. CA Cancer J Clin 2001;51:273-85.
3. **Bergsal D.** The incidence and the epidemiology of the plasma cellneoplasms. Stem cells 1995; (suppl-2):1-9.
4. **Boccardo M, Pileri A.** The diagnosis, prognosis, and the standard treatment of multiple myeloma. Hematol Oncol Clin North Am 1997;11:111-31.
5. **Bottini, Virginia P.** Laboratory tests for the evaluation of the monoclonal component. Rev. Bras. Hematol. Hemoter. 2007, 29 (1): 23-26.

6. **Breitkreutz I, Lokhorst HM, Rabb MS, Hold B Vander, Cremer FW, Herman D, Glasmacher A, Schmidt wolf IGH, Blan IW** diagnosed multiple myeloma: the influence of the thalidomide treatment on the peripheral blood stem cell collection yield. *Laeukemia* 2007;21: 1294-99.
7. **Chopra GS, Gupta PK, Mishra DK.** The evaluation of suspected monoclonal gammopathies: the experience in a tertiary care hospital. *MJAFI* 2006; 62:134-37.
8. **Dilawar M, Ijaz A, Hafeez A, Akbar N, Khan FA.** The pattern of serum protein electrophoresis in various diseases. *Pak J Pathol.* 2005;16(1):22-27.
9. **Durie BG.** The staging and the kinetics of multiple myeloma. *Seminars in Oncology.*1986;13:300-9.
10. **George ED, Sadosky R.** Multiple myeloma: recognition and management. *Am Fam Physician* 1999;59(7):1885-94.
11. **Ishida T, Dorfman HD.** Plasma cell myeloma in unusually young patients. *Skeletal Radiol* 1995;24: 47-51.
12. **Kyle RA, Rajkumar S V. Monoclonal gammopathies of undetermined significance.** *Hematol Oncol Clin North Am* 1999;13:1181–202 PMID: 1062-44.
13. **Kyle RA, Rajkumar S V.** Monoclonal gammopathies of undetermined significance. *Br J Haematol* 2006; 134:573–89 PMID: 16938117.
14. **Kyle RA, Rajkumar SV.** The criteria for the diagnosis, staging, risk stratification and the response assessment of multiple myeloma. *Leukemia.* 2009. January; 23(1):3-9.
15. **Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, et al. 3rd.**A long-term study on the prognosis of monoclonalgammopathy, of an undetermined significance. *N Engl JMed* 2002;346:564–9 PMID: 11856795.
16. **Kyle RA.** Multiple myeloma – an overview. *The Oncologist* 1996;1: 315-23.
17. **Kyle RA. Multiple Myeloma:** An overview in 1996. *The Oncologist* 1996;1:315-23.
18. **Kyle, RA.** Monoclonal gammopathy of uncertain significance; the natural history in 241 cases. *Mayo Clinic Proceedings* 1978; 50: 29–40.
19. **Mehta KD, Khambu B, Lakhey M, Lakhey S, Baral N, Majhi S.** The diagnosis of multiple myeloma by the demonstration of the M protein in the bone marrow aspirate, by agar gell electrophoresis: A case report. *Kathmandu University Medical Journal* 2006, 4, No 4, Issue 16: 513-16.
20. **Nayak BS, Mungrue K, Gopee D, Friday M, Garcia S, Hirschfeld E,** The epidemiology of multiple myeloma and the role of the M band detection on the serum electrophoresis in a small developing country. A retrospective study. *Arch Physiol Biochem.*2011 Oct; 117(4): 236-40.
21. **O’Connell TX, Horita TJ, Kasravi B.** Understanding and interpreting serum protein electrophoresis. *Am Fam Physician.* 2005 Jan 1;(1): 105-12.
22. **The International Myeloma Working Group.** The criteria for the classification of the monoclonal gammopathies, multiple myeloma and the related disorders. *Br J Hematol.* 2003;121:749-57.
23. **Vavricka SR, Burri E, Beglinger C, Degen L.** Serum protein electrophoresis: An underused but very useful test. *Digestion* 2009;79: 203-10 .
24. **Vijayashree N .**The serum protein electrophoresis pattern in the chronically ill patients in a tertiary care hospital. *Ind J Clin Biochem.* 2009; 24,supp-, P 204.